[December 15, 2017] |
|
Combigan 2016-2017 U.S. Promotional Report - Research and Markets
The "Combigan
2016 U.S. Promotional Report" report has been added to Research
and Markets' offering.
The 5 Key Questions Addressed by this Report:
-
How many physicians were reached by Combigan through personal
promotion in 2016 and how does this compare to its peer set in the
Glaucoma markets?
-
What promotional mix was leveraged (e.g., sales rep detailing,
physician education, and paid speaking) and what was the median spend
on each type of activity?
-
How does Allergan's depth of coverage vary within key specialties
(e.g., Ophthalmology, Optometry, Dermatology, Plastic Surgery,
Neurology, and Urology) and how does this compare to its peers and the
overall et of rep-accessible physicians?
-
How often are physicians receiving paid meals for Combigan throughout
the year (e.g., monthly, quarterly, annually)?
-
Who were the most detailed prescribers and top paid speakers for
Combigan in 2016?
Data Sources and Methodology:
-
We leverage company-reported financial transaction data disclosed
through CMS Open Payments. This data set captures all transfers of
value (e.g., speaking fees, consulting fees, travel, education, and
meals) made on behalf of a drug or device manufacturer to a physician.
Currently, 42 months of longitudinal data is available - covering
payments to more than 900,000 U.S. healthcare professionals.
-
Over 4,200 paid interactions across 3,100 physicians made on behalf of
Combigan were carefully examined to support our analysis. In addition,
interaction data from 6 peer products (e.g. Alphagan P, Istalol,
Lumigan, Simbrinza, Travatan Z, and Zioptan) was leveraged to provide
benchmarking and market insights.
For more information about this report visit https://www.researchandmarkets.com/research/mk223q/combigan?w=4
View source version on businesswire.com: http://www.businesswire.com/news/home/20171215005713/en/
[ Back To TMCnet.com's Homepage ]
|